Clinical Trial

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Active, Not Recruiting Phase 4

Summary

This clinical trial studies cognitive function in men with prostate cancer treated with androgen receptor directed therapies such as abiraterone acetate and enzalutamide. The investigators use MRI imaging (non-invasive, non-contrast) to see whether there are changes in brain structure or activity related to treatment that may be related to changes in cognitive function. The investigators are also looking for genetic variations that might make patients more or less sensitive to cognitive changes during treatment for prostate cancer.

Protocol Amendment History 9 amendments

This ClinicalTrials.gov record has been amended 9 times since 2017-01-06; most recent amendment 2026-02-20.

Status change: Recruiting → Active, Not Recruiting 2025-04-23

Status change: Not Yet Recruiting → Recruiting 2017-05-22

Trial Details

NCT Number	NCT03016741
Lead Sponsor	Northwestern University
Conditions	Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Refractory Prostate Cancer
Enrollment	100 participants
Start Date	2017-03-31
Primary Completion	2023-01-04 (estimated)
Study Completion	2029-08 (estimated)
Updated on ClinicalTrials.gov	2026-02-24